FDA Needs New Standards for Studying Alzheimer's Drugs
In the end, it may turn out that attacking today's biomarkers may not prevent Alzheimer's. The answer, though, won't be known unless the FDA revises its rules, a gamble we may want to take given the alternative.
Tia Powell, Contributor
Director, Montefiore Einstein Center for Bioethics